hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06341283 id: BCOOS2024 briefTitle: A Retrospective Real-world Study of Abemaciclib Tablets Based on HIS System in HR+ Breast Cancer Patients overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-12-31 date: 2025-07-01 date: 2024-04-02 date: 2024-04-02 name: The Affiliated Hospital of Qingdao University class: OTHER briefSummary: The present study will assess real-world clinical outcomes, adverse events and economics from treatment with endocrine therapy combined with abemaciclib in patients with HR-positive breast cancer. conditions: Breast Cancer conditions: Neoplasms conditions: Breast Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 200 type: ESTIMATED name: Abemaciclib and Letrozole/Anastrozole name: Letrozole or Anastrozole name: Abemaciclib and Fulvestrant name: Fulvestrant measure: Progression-free survival measure: Objective Remission Rate measure: Disease Control Rate measure: Toxicity rate measure: Cost-utility analysis sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinical Research Center city: Qingdao state: Shandong country: China lat: 36.06488 lon: 120.38042 hasResults: False
nctId: NCT06341257 id: VGHTCCTC_SCART001 briefTitle: Efficacy and Toxicity of SCART overallStatus: RECRUITING date: 2024-01-01 date: 2026-12-31 date: 2029-12-31 date: 2024-04-02 date: 2024-04-02 name: Taichung Veterans General Hospital class: OTHER briefSummary: This study is expected to enroll patients for a period of five years, with a total of 30 participants. It is a prospective observational study involving cancer patients with tumors having a longest diameter greater than or equal to 5 cm. Systemic drug therapy may be administered concurrently. The following inclusion criteria must be met for participation in the study: age greater than or equal to 18 years, Eastern Cooperative Oncology Group (ECOG) score ≤ 2, pathological confirmation of cancer diagnosis, tumor with a maximum diameter greater than or equal to 5 cm, one or more lesions, not suitable for surgery, patient has provided informed consent, patient receives SCART, and reproductive-age women must agree to take adequate contraceptive measures during the study and for six months after discontinuation of medication. The patient will receive a dose of 21 Gy in 3 fractions, with the dose maintained at 5 Gy per fraction for the entire tumor gross target volume (GTV) boundary. For certain patients, an additional two fractions of 5 Gy each were added using Stereotactic Body Radiotherapy (SBRT), resulting in a total dose of 5 Gy × 5 for the GTV boundary. conditions: Tumor Size Greater Than or Equal to 5 cm studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Stereotactic Central/Core Ablative Radiation Therapy (SCART) measure: Local Control (LC) measure: Progression-Free Survival (PFS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taichung Veterans General Hospital status: RECRUITING city: Taichung zip: 407 country: Taiwan name: Hao-Shen Cheng, MD role: CONTACT phone: 886975871151 email: mark89050921@gmail.com lat: 24.1469 lon: 120.6839 hasResults: False
nctId: NCT06341244 id: UNIFESP briefTitle: Air Stacking Technique Efficacy on Peak of Expiratory Flow and Cough Peak Flow in Non-cardiac Thoracic Surgery overallStatus: COMPLETED date: 2019-08-20 date: 2020-11-05 date: 2022-12-15 date: 2024-04-02 date: 2024-04-02 name: Universidade Cidade de Sao Paulo class: OTHER name: Federal University of São Paulo briefSummary: After thoracic surgical intervention, patients often feel intense pain with respiratory movements reduction making coughing less effective. The air stacking improves peak of expiratory flow (PEF) and cough peak flow (CPF) in neuro myopathies, thus raising the hypothesis that may also be effective in patients undergoing thoracic surgeries. Objectives: To evaluate the effectiveness, safety and feasibility of air stacking on postoperative PEF and CPF in patients undergoing thoracic surgeries. Methods: Patients undergoing thoracic surgery underwent air stacking on 3th PO. Dyspnea, pain, SpO2, maximum inspirational pressure (MIP), maximum expiratory pressure (MEP), PEF and CPF were evaluated in pre and postoperatory. conditions: Postoperative Care studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ACTUAL name: Air Stacking Technique measure: Peak of expiratory flow (PEF) measure: Cough peak flow (CPF) measure: Maximum Inspiratory Pressure ( MIP) measure: Maximun Expiratory Pressure (MEP) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Luciana Chiavegato city: São Paulo zip: 04115000 country: Brazil lat: -23.5475 lon: -46.63611 hasResults: False
nctId: NCT06341231 id: 202400248 briefTitle: Personalized Anticoagulant Therapy for Pulmonary Thromboembolism overallStatus: RECRUITING date: 2024-02-01 date: 2026-12-31 date: 2027-12-31 date: 2024-04-02 date: 2024-04-02 name: Xiangya Hospital of Central South University class: OTHER briefSummary: The goal of this prospective observational study is to explore the influencing factors of the efficacy and safety of anticoagulant therapy for pulmonary thromboembolism in special populations with older age, renal insufficiency or co-existing malignancy, and establish a predictive model to guide clinical practice. The main questions it aims to answer are:
* Whether we can use machine-learning models to predict bleeding events and VTE recurrence in special populations following anticoagulant therapy in the real world? Participants will receive diagnostic and therapeutic measures for pulmonary thromboembolism in accordance with clinical guidelines, including anticoagulant therapy. Some patients need to have peripheral blood samples collected at the time of enrollment and 3 months after anticoagulant therapy. conditions: Pulmonary Thromboembolisms conditions: Anticoagulants; Increased studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 4700 type: ESTIMATED measure: Major bleeding measure: Clinically relevant non-major bleeding measure: Recurrent VTE measure: All-cause mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xiangya Hospital status: RECRUITING city: Changsha state: Hunan zip: 410008 country: China name: Juan Jiang, MD role: CONTACT phone: +8615388078713 email: juanjiang@csu.eud.cn lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06341218 id: 21-5T/3 briefTitle: The Effect Of Simulation-Supported Pediatric CPR Training Based On CRM On Knowledge, Attitude, And Performance overallStatus: COMPLETED date: 2021-02-25 date: 2023-09-30 date: 2023-11-15 date: 2024-04-02 date: 2024-04-02 name: Zonguldak Bulent Ecevit University class: OTHER name: Ege University briefSummary: Crew Resource Management is a training system that aims to use all available resources effectively and increase safety by improving technical knowledge and skills as well as non-technical skills in risky tasks such as CPR. In safe critical patient management, the healthcare team should have interpersonal skills such as communication, stress management, teamwork, and leadership, cognitive skills such as situational awareness, task completion, planning, monitoring the situation, and rapid response to critical incidents, in addition to technical skills. To improve outcomes after pediatric cardiac arrest, many systems have been developed for performance measurement and quality improvement initiatives of the healthcare team. However, studies are needed to evaluate the effects of these systems. This study was planned to evaluate the effectiveness of simulation-supported pediatric cardiopulmonary resuscitation training based on team resource management on knowledge, attitude, and performance of the healthcare team in the pediatric intensive care unit. conditions: Cardiopulmonary Resuscitation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: PARTICIPANT count: 70 type: ACTUAL name: Pediatric Cardiopulmonary Resuscitation Training Based On Team Resource Management measure: Socio-demographic data of the healthcare team measure: Pediatric KPR knowledge level measure: Pediatric KPR team attitude level measure: Pediatric KPR team performance level sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Ege University city: İzmir state: Bornova zip: 35100 country: Turkey lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06341205 id: 22-APN-01 briefTitle: Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) acronym: iRITUX overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2031-08-31 date: 2031-09-30 date: 2024-04-02 date: 2024-04-02 name: Centre Hospitalier Universitaire de Nice class: OTHER briefSummary: Membranous nephropathy is an autoimmune disease affecting the kidney, and the most common cause of nephrotic syndrome in non-diabetic Caucasian adults. The course of this disease is highly variable from one individual to another, ranging from spontaneous remission to progressive chronic kidney disease.
The identification of autoantibodies - e.g., the phospholipase A2 receptor type 1 (PLA2R1) - has promoted the use of immunosuppressive drugs such as rituximab which is now a safe and effective first-line treatment for the management of membranous nephropathy. However, up to 40% of patients do not respond to a first course of rituximab treatment. In nephrotic patients, due to urinary drug loss, rituximab blood level is lower than in other autoimmune diseases treated with rituximab without proteinuria. This high urinary drug loss decreases the drug exposure, potentially explaining why rituximab regimen with low dose infusions (375 mg/m2) did not demonstrate efficacy after month-6 compared to a non-immunosuppressive antiproteinuric treatment in a previous study. In contrast, a regimen of two 1-g infusions two weeks apart was associated with a significantly greater remission rate after 6 months.
Recently, the investigators have shown that after two 1-g rituximab infusions, the rituximab blood level 3 months after the first rituximab infusion, was correlated with the likelihood of remission after 6 and 12 months of the rituximab treatment. Patients with positive rituximab blood level 3 months after treatment had a higher chance of remission at month-6 and at month-12 than patients with an undetectable rituximab level at month-3.
The objective of this study is to use a machine learning algorithm predicting the risk of having an undetectable residual level of rituximab 3 months after treatment, in order to propose a personalized treatment management with early additional doses of rituximab for the patients at risk. conditions: Membranous Nephropathy studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: RiTUXimab Injection measure: Clinical remission (complete or partial) after 6 months of rituximab initiation measure: Complete clinical remission after 12 months of rituximab initiation measure: Partial clinical remission after 12 months of rituximab initiation measure: Immunological remission: anti-PLA2R1 depletion measure: Change in urine protein/creatinine ratio (UPCR) measure: Change in serum creatinine measure: Change in renal function measure: Change in the immunological status of the disease measure: Appearance of anti-drug antibodies after rituximab treatment measure: Rituximab underdosed patients measure: Serious adverse events measure: Adaptation of symptomatic treatment measure: Model improvement through machine learning measure: Effect of rituximab on immune profiles sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06341192 id: ChangGungMH ALL SB DB briefTitle: Comparison Between Combined ALLR With Single Bundle and Double Bundle Anterior Cruciate Ligament Reconstruction acronym: ALLR overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-08-31 date: 2026-10-31 date: 2024-04-02 date: 2024-04-26 name: Chang Gung Memorial Hospital class: OTHER briefSummary: The goal of this clinical trial is to test and compare different surgical techniques in patients with anterior cruciate ligament (ACL) injuries. The main questions it aims to answer are:
Researchers will compare the single-bundle ACL + ALL group and the double-bundle ACL + ALL group to see if one technique demonstrates superior knee stability, functional outcomes (e.g. return to sport ability), and lower ACL re-tear rates. conditions: Anterior Cruciate Ligament Injuries conditions: Anterior Cruciate Ligament Reconstruction studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Single-Bundle ACL + ALL Reconstruction Group:
* The double-bundle ACL reconstruction aims to better restore the ACL's complex anatomic footprint and bundles' tension patterns. primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Single-bundle ACL combined anterolateral ligament reconstruction name: Double-bundle ACL combined anterolateral ligament reconstruction measure: Patient-reported outcome measures (PROMs) measure: Patient-reported outcome measures (PROMs) measure: Patient-reported outcome measures (PROMs) measure: Knee ligament stability: measure: Knee ligament stability clinical evaluation measure: Knee ligament stability clinical evaluation measure: Knee ligament stability clinical evaluation measure: Functional performance and return to sport measure: Functional performance and return to sport measure: Imaging measure: Imaging sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chang Gung memorial hospital city: Taoyuan zip: 333 country: Taiwan name: Cheng-Pang Yang, Dr role: CONTACT email: ronnie80097@gmail.com lat: 24.95233 lon: 121.20193 hasResults: False
nctId: NCT06341179 id: M2S id: H-23063352 type: OTHER domain: Vek.dk briefTitle: Effect of Sleep Extension on Overweight and Learning in Children acronym: More2Sleep overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-12-31 date: 2027-12-31 date: 2024-04-02 date: 2024-04-02 name: University of Copenhagen class: OTHER name: Novo Nordisk A/S name: Faculty of Health, Medicine and Life Sciences, Maastricht University name: Center for Obesity Research & Education, Temple University name: Danish Research Centre for Magnetic Resonance name: University of Southern Denmark briefSummary: More2Sleep is a randomized, controlled, parallel trial with two groups (sleep extension vs control) including 300 school-aged children (6-9 years) who are mildly overweight or obese and habitually sleep for ≤ 9 h/night. Data will be collected before and after a 3-month sleep extension intervention, and after a 6-month follow-up (at months 0, 3, and 9). The collection of data is mainly related to the main study. However, some optional examinations will be conducted on a first come, first serve basis, consisting of substudy-I (metabolic mechanisms, n=60) and substudy-II (learning mechanisms, n=150).
nctId: NCT06341166 id: CCM1959 briefTitle: Multiparametric SCores for Prediction of Myocardial fIbrosis in Patients With MITral vAlve pRolapse acronym: SCIMITAR overallStatus: RECRUITING date: 2023-06-19 date: 2025-06-19 date: 2025-06-19 date: 2024-04-02 date: 2024-04-02 name: Centro Cardiologico Monzino class: OTHER name: Treviso Regional Hospital name: Humanitas Hospital, Italy name: IRCCS Ospedale San Raffaele briefSummary: This is a multicenter, observational prospective and retrospective study which aims are: 1) to compute a scoring model potentially predictive for the diagnosis of fibrosis by CMR in patients with MVP; 2) to identify specific features that may predispose to ≥ mild VAs or SCD in patients with MVP. conditions: Mitral Valve Prolapse studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 300 type: ESTIMATED measure: Prediction of fibrosis by CMR measure: Prediction of ≥ mild Ventricular Arrhythmias and/or Sudden cardiac death in mitral valve sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centro Cardiologico Monzino status: RECRUITING city: Milan zip: 20131 country: Italy name: Chiara Centenaro role: CONTACT phone: 0258002031 phoneExt: +39 email: chiara.centenaro@cardiologicomonzino.it lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06341153 id: SelcukUni2542 briefTitle: The Effect Of Breast Milk Sniffing And Tasting On Early Feeding Tips overallStatus: COMPLETED date: 2022-07-15 date: 2022-09-15 date: 2023-11-15 date: 2024-04-02 date: 2024-04-02 name: Sibel Küçükoğlu class: OTHER name: Health Institutes of Turkey briefSummary: The study aimed to investigate the effects of breast milk sniffing and breast milk tasting and sniffing on sucking success and early feeding cues in term newborns who were started to breastfeed for the first time. conditions: Breastfeeding conditions: Odors, Body conditions: Newborn; Vitality studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The stratification and blocking method was used to assign the mothers who would participate in the study to the experimental and control groups, taking into account factors such as normal or cesarean delivery and breastfeeding experience. In order to ensure homogeneity in the groups, mothers were stratified as mode of delivery (Normal-Cesarean) and breastfeeding experience (Present-Non-existent). After the blocks were formed, the groups included in the study were randomly assigned to the strata with the letters A, B and C using the random numbers table obtained in the computer environment (www.random.org). Which letter would be in which group was determined by lot (A=Odor Stimulation, B=Odor+Taste Stimulation, C=Control Group). primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: According to the a priori power analysis with a pairwise hypothesis, effect size of 0.409, significance level of 0.05 and power of 0.80; it was determined that the inclusion of a total of 72 newborns (Odor Stimulation: 24, Odor+taste stimulation: 24, Control: 24) in the study would provide sufficient sample size.
* Apgar score of 7 and above. whoMasked: INVESTIGATOR count: 72 type: ACTUAL name: Breast Milk Odor Stimulation name: Stimulation of Breast Milk Smell and Taste measure: Introductory Information Form measure: Early Feeding Tips Scale measure: Breastfeeding Identification and Assessment Scale (LATCH) measure: Early Feeding Tips Scale measure: Breastfeeding Identification and Assessment Scale (LATCH) measure: Early Feeding Tips Scale measure: Breastfeeding Identification and Assessment Scale (LATCH) sex: FEMALE minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Selcuk University city: Konya state: Selcuklu zip: 42100 country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False
nctId: NCT06341140 id: secil koken briefTitle: The Effect of Breastfeeding Support on Exclusive Breastfeeding, Occurrence of Breast Problems and Breastfeeding Self-Efficacy overallStatus: COMPLETED date: 2021-08-01 date: 2022-11-30 date: 2023-02-06 date: 2024-04-02 date: 2024-04-02 name: Celal Bayar University class: OTHER name: Manisa Celal Bayar University briefSummary: The aim of the study is to determine the effect of individual breastfeeding support on the lactation process. The research is a randomized controlled experimental study. The sample of the study consisted of pregnant women who applied to the Obstetrics Polyclinic of a university hospital (intervention=51, control=51). In the study, individual breastfeeding education was given to the intervention group during the antenatal period, and a training booklet was given to the control group. In the postpartum period, home visits and phone follow-ups were carried out for both groups between the fifth day and the sixth month. The effect of breastfeeding counseling on the lactation process; The duration of exclusive breastfeeding, breast problems and breastfeeding success was evaluated with. The data of the study were collected using the Pregnant, Postpartum-Newborn Information Form, Breastfeeding Questionnaire, Breast Problems Diagnosis Form, LATCH Breastfeeding Diagnostic Tool and Breastfeeding Self-Efficacy Scale. conditions: Breastfeeding conditions: Breastfeeding, Exclusive studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 102 type: ACTUAL name: Breastfeeding support and Booklet containing information about breastfeeding name: Booklet containing information about breastfeeding measure: Situation of mothers feeding their babies exclusively with breast milk measure: Mothers experiencing breast problems measure: Determination of mothers' breastfeeding self-efficacy sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Manisa Celal Bayar University city: Manisa country: Turkey lat: 38.61202 lon: 27.42647 hasResults: False
nctId: NCT06341127 id: 2023-01 briefTitle: Fluoxetine in KCNC1-related Disorder overallStatus: ENROLLING_BY_INVITATION date: 2024-01-17 date: 2024-12-01 date: 2025-12-31 date: 2024-04-02 date: 2024-04-02 name: Holland Bloorview Kids Rehabilitation Hospital class: OTHER name: The Hospital for Sick Children briefSummary: This is a single patient study of oral powdered fluoxetine to target developmental outcomes in a child with KCNC1-related disorder. This trial will be conducted at Holland Bloorview Kids Rehabilitation Hospital over 32 to 42 weeks, using a quasi experimental ABA phase design (placebo-fluoxetine-placebo) with randomized and blinded active treatment start and stop moments. conditions: KCNC1 Related Disorder conditions: Genetic Disease conditions: Rare Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE maskingDescription: This quasi experimental design involves masking of transition moments, but the investigator and participant are aware of the order of cross-over. count: 1 type: ESTIMATED name: Fluoxetine measure: Motor development measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] measure: Adaptive skills measure: Cognitive skills measure: Family priority outcome targets measure: Clinical Global Impression- Improvement Scale (CGI-I) sex: ALL maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Holland Bloorview Kids Rehabilitation Hospital city: Toronto state: Ontario zip: M5G1R8 country: Canada lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06341114 id: BAT-8008-1308-001-CR briefTitle: A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-04-12 date: 2026-04-03 date: 2026-07-28 date: 2024-04-02 date: 2024-04-02 name: Bio-Thera Solutions class: INDUSTRY briefSummary: The study, led by Zhejiang Cancer Hospital and sponsored by Bio-Thera Solutions, Ltd., is an exploratory multicenter, open-label phase Ib-II clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of the combination of BAT8008 with BAT1308 in patients with advanced solid tumors.